For instance, research has reported on the clinical efficacy of PARPi, either as a single agent or in combination with existing treatment regimens, in ameliorating outcome in BC patients with germline mutations in BRCA1/2 and PALB2, as well as BRCAness38–40. Here, PALB2 is linked to breast cancer.